Immunohistochemical staining

PreclinicalBiologic

Immunohistochemical staining is one of 78 biologic programs targeting Colorectal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Colorectal CarcinomaPreclinical

Active, not recruiting

Cutaneous Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Sutent

Pfizer

Phase 3

1 3

Iressa

AstraZeneca

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

5 5

Vectibix

Golytely

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

1 10

Camptosar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Colorectal Carcinoma

NCT07047482

Clinical

Trials by Indication[1]

Colorectal Carcinoma2 trials

Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma

Unknown status·SSohag University··NCT05794737·60 enrolled

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

Recruiting·SSohag University··NCT07047482·50 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers

Recruiting·SSohag University··NCT06536946·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Immunohistochemical staining. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunohistochemical staining compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunohistochemical staining. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: SSohag University

Immunohistochemical staining

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Colorectal Carcinoma2 trials

Cutaneous Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News